儿童艰难梭菌感染:流行病学、诊断与治疗的最新进展
本文综述儿童艰难梭菌感染(CDI)的流行病学、诊断与治疗进展。诊断难以区分定植与感染,复发率20%–30%。甲硝唑长期为主要治疗,新证据支持口服万古霉素和非达霉素,粪菌移植用于复发性感染。
要点
- 儿童CDI以社区相关感染为主,占全部病例的四分之三。
- 现有检测无法区分定植与感染,婴幼儿等群体定植率高,需生物标志物辅助诊断。
- 复发常见,影响20%–30%的初发病例;口服万古霉素和非达霉素有安全有效性新证据。
核心结论
- 甲硝唑长期为主要治疗,但新证据支持口服万古霉素和非达霉素作为额外选择,粪菌移植用于复发性感染。
研究设计与样本
- 本文为综述,汇总儿童CDI流行病学、诊断与治疗的最新进展。
主要发现
- 疾病谱从无症状携带到严重腹泻,暴发性疾病在儿童中罕见但可致高发病率甚至死亡。
- 复发影响20%–30%的初发病例。
关键数值与推荐
- 现有检测可检测病原体或致病毒素,但无法区分定植与感染。
- 甲硝唑长期被视为儿童CDI的主要治疗。
- 新证据支持口服万古霉素和非达霉素的安全性和有效性。
- 粪菌移植用于复发性感染。
临床怎么用
- 儿童CDI诊断需注意现有检测无法区分定植与感染,婴幼儿定植率高。
- 治疗可考虑甲硝唑,新证据支持口服万古霉素和非达霉素作为额外选择。
- 复发性感染可考虑粪菌移植。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clostridioides (formerly Clostridium) difficile is the most important infectious cause of antibiotic-associated diarrhea worldwide and a leading cause of healthcare-associated infection in the United States. The incidence of C. difficile infection (CDI) in children has increased, with 20 000 cases now reported annually, also posing indirect educational and economic consequences. In contrast to infection in adults, CDI in children is more commonly community-associated, accounting for three-quarters of all cases. A wide spectrum of disease severity ranging from asymptomatic carriage to severe diarrhea can occur, varying by age. Fulminant disease, although rare in children, is associated with high morbidity and even fatality. Diagnosis of CDI can be challenging as currently available tests detect either the presence of organism or disease-causing toxin but cannot distinguish colonization from infection. Since colonization can be high in specific pediatric groups, such as infants and young children, biomarkers to aid in accurate diagnosis are urgently needed. Similar to disease in adults, recurrence of CDI in children is common, affecting 20% to 30% of incident cases. Metronidazole has long been considered the mainstay therapy for CDI in children. However, new evidence supports the safety and efficacy of oral vancomycin and fidaxomicin as additional treatment options, whereas fecal microbiota transplantation is gaining popularity for recurrent infection. Recent advancements in our understanding of emerging epidemiologic trends and management of CDI unique to children are highlighted in this review. Despite encouraging therapeutic advancements, there remains a pressing need to optimize CDI therapy in children, particularly as it pertains to severe and recurrent disease.
引用
- Shirley DA, Tornel W, Warren CA, et al. Clostridioides difficile Infection in Children: Recent Updates on Epidemiology, Diagnosis, Therapy. Pediatrics. 2023. PMID: 37560802. doi:10.1542/peds.2023-062307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。